Table 5. Multivariate Cox proportional... | American Society of Hematology

Table 5.

Multivariate Cox proportional hazards analysis of leukemia-free survival for all participating patients (n = 320) and patients in CR1 (n = 261)

Variable	Hazard ratio	95% CI	P^*
All patients
Treatment (HDC/IL-2 vs control)†	0.69	(0.52-0.90)	< .01
Age, y (≤ 60 vs > 60)	0.66	(0.50-0.88)	< .01
Sex (men vs women)	1.31	(0.99-1.73)	.06
FAB class
M0/M1/M5/M6 (no vs yes)	1.23	(0.73-2.07)	.44
M2/M3/M4 (no vs yes)	1.67	(0.99-2.80)	.05
Karyotype (MRC)
Favorable (no vs yes)	0.88	(0.50-1.57)	.67
Intermediate (no vs yes)	1.03	(0.74-1.45)	.84
Adverse (no vs yes)	0.50	(0.27-0.93)	.03
Patients in CR1
Treatment (HDC/IL-2 vs control)†	0.67	(0.50-0.91)	.01
Age, y (≤ 60 vs > 60)	0.75	(0.52-1.07)	.12
FAB class
M0/M1/M5/M6 (no vs yes)	1.04	(0.57-1.89)	.90
M2/M3/M4 (no vs yes)	1.66	(0.91-3.04)	.10
Karyotype (MRC)
Favorable (no vs yes)	0.75	(0.40-1.40)	.37
Intermediate (no vs yes)	0.96	(0.65-1.42)	.86
Adverse (no vs yes)	0.52	(0.27-0.99)	< .05
History of antecedent hematologic disorder (no vs yes)	0.76	(0.49-1.16)	.20
High-dose cytarabine therapy (no vs yes)	1.43	(0.97-2.12)	.08
Months from current CR to random assignment (≤ 6 vs > 6)	1.48	(1.01-2.16)	< .05

Variable	Hazard ratio	95% CI	P^*
All patients
Treatment (HDC/IL-2 vs control)†	0.69	(0.52-0.90)	< .01
Age, y (≤ 60 vs > 60)	0.66	(0.50-0.88)	< .01
Sex (men vs women)	1.31	(0.99-1.73)	.06
FAB class
M0/M1/M5/M6 (no vs yes)	1.23	(0.73-2.07)	.44
M2/M3/M4 (no vs yes)	1.67	(0.99-2.80)	.05
Karyotype (MRC)
Favorable (no vs yes)	0.88	(0.50-1.57)	.67
Intermediate (no vs yes)	1.03	(0.74-1.45)	.84
Adverse (no vs yes)	0.50	(0.27-0.93)	.03
Patients in CR1
Treatment (HDC/IL-2 vs control)†	0.67	(0.50-0.91)	.01
Age, y (≤ 60 vs > 60)	0.75	(0.52-1.07)	.12
FAB class
M0/M1/M5/M6 (no vs yes)	1.04	(0.57-1.89)	.90
M2/M3/M4 (no vs yes)	1.66	(0.91-3.04)	.10
Karyotype (MRC)
Favorable (no vs yes)	0.75	(0.40-1.40)	.37
Intermediate (no vs yes)	0.96	(0.65-1.42)	.86
Adverse (no vs yes)	0.52	(0.27-0.99)	< .05
History of antecedent hematologic disorder (no vs yes)	0.76	(0.49-1.16)	.20
High-dose cytarabine therapy (no vs yes)	1.43	(0.97-2.12)	.08
Months from current CR to random assignment (≤ 6 vs > 6)	1.48	(1.01-2.16)	< .05

Included in this model are variables selected from a backward selection process. P values were calculated using the Wald test and stratified by country and, if applicable, CR stratum.

†

Of the dichotomized groups, the second group is always the baseline.

View Large

This Feature Is Available To Subscribers Only